ArticleJournal of medical biochemistry2025

Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np).

Lingyan Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.